AR and breast carcinoma: Luminal androgen receptor (LAR) subtype TNBC patients defined by our TNBC type are less responsive to NAC compared to other TNBC subtypes [58,59], but breast cancer patients with positive androgen receptor (AR) expression have favorable long-term clinical outcomes, including overall survival and recurrence [60,61].